Alzheimer Disease Clinical Trial
— ADVANCEOfficial title:
A Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of AXS-05 for the Treatment of Agitation in Subjects With Dementia of the Alzheimer's Type
Verified date | August 2023 |
Source | Axsome Therapeutics, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a multi-center, randomized, double-blind, placebo-controlled study, to assess the efficacy and safety of AXS-05 in the treatment of agitation in patients with Alzheimer's disease.
Status | Completed |
Enrollment | 366 |
Est. completion date | April 17, 2020 |
Est. primary completion date | April 17, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 65 Years to 90 Years |
Eligibility | Key Inclusion Criteria: - Diagnosis of probable Alzheimer's disease (AD) based on the 2011 National Institute on Aging-Alzheimer Association (NIA-AA) criteria. - Diagnosis of clinically signification agitation resulting from probable AD according to the International Psychogeriatric Association (IPA) provisional definition of agitation. Exclusion Criteria: - Patient has dementia predominantly of non-Alzheimer's type. - Unable to comply with study procedures. - Medically inappropriate for study participation in the opinion of the investigator. |
Country | Name | City | State |
---|---|---|---|
Australia | Axsome study site | Caulfield | Melbourne, Victoria |
United States | Axsome Study Site | Albany | New York |
United States | Axsome Study Site | Apopka | Florida |
United States | Axsome study site | Atlanta | Georgia |
United States | Axsome study site | Avon | Indiana |
United States | Axsome study site | Baton Rouge | Louisiana |
United States | Axsome study site | Bellevue | Washington |
United States | Axsome study site | Boca Raton | Florida |
United States | Axsome study site | Boise | Idaho |
United States | Axsome study site | Boynton Beach | Florida |
United States | Axsome study site | Brooklyn | New York |
United States | Axsome study site | Canoga Park | California |
United States | Axsome Study Site | Charlotte | North Carolina |
United States | Axsome study site | Charlotte | North Carolina |
United States | Axsome Study Site | Charlottesville | Virginia |
United States | Axsome study site | Chesterfield | Missouri |
United States | Axsome study site | Cincinnati | Ohio |
United States | Axsome Study Site | Coconut Creek | Florida |
United States | Axsome Study Site | Colorado Springs | Colorado |
United States | Axsome study site | Costa Mesa | California |
United States | Axsome study site | Cromwell | Connecticut |
United States | Axsome Study Site | Dayton | Ohio |
United States | Axsome study site | Decatur | Georgia |
United States | Axsome study site | DeSoto | Texas |
United States | Axsome Study Site | Everett | Washington |
United States | Axsome Study Site | Flossmoor | Illinois |
United States | Axsome study site | Fresno | California |
United States | Axsome Study Site | Gilbert | Arizona |
United States | Axsome Study Site | Greenacres City | Florida |
United States | Axsome study site | Hallandale Beach | Florida |
United States | Axsome Study Site | Hattiesburg | Mississippi |
United States | Axsome study site | Hialeah | Florida |
United States | Axsome Study Site | Honolulu | Hawaii |
United States | Axsome Study Site | Lake Charles | Louisiana |
United States | Axsome Study Site | Lake City | Florida |
United States | Axsome study site | Las Vegas | Nevada |
United States | Axsome Study Site | Las Vegas | Nevada |
United States | Axsome Study Site | Little Rock | Arkansas |
United States | Axsome study site | Long Beach | California |
United States | Axsome study site | Long Beach | California |
United States | Axsome Study Site | Los Alamitos | California |
United States | Axsome Study Site | McKinney | Texas |
United States | Axsome study site | Miami | Florida |
United States | Axsome study site | Miami | Florida |
United States | Axsome study site | New London | Connecticut |
United States | Axsome study site | New York | New York |
United States | Axsome study site | New York | New York |
United States | Axsome Study Site | Oklahoma City | Oklahoma |
United States | Axsome study site | Orem | Utah |
United States | Axsome Study Site | Orlando | Florida |
United States | Axsome Study Site | Overland Park | Kansas |
United States | Axsome study site | Pensacola | Florida |
United States | Axsome Study Site | Phoenix | Arizona |
United States | Axsome Study Site | Port Orange | Florida |
United States | Axsome Study Site | Princeton | New Jersey |
United States | Axsome Study Site | Richmond | Virginia |
United States | Axsome study site | Riverside | California |
United States | Axsome study site | Sacramento | California |
United States | Axsome Study Site | Saint Louis | Missouri |
United States | Axsome study site | Santa Ana | California |
United States | Axsome Study Site | Santa Clarita | California |
United States | Axsome study site | Scottsdale | Arizona |
United States | Axsome study site | Scottsdale | Arizona |
United States | Axsome study site | Shaker Heights | Ohio |
United States | Axsome study site | Sherman Oaks | California |
United States | Axsome study site | Simi Valley | California |
United States | Axsome study site | Spokane | Washington |
United States | Axsome study site | Spring Hill | Florida |
United States | Axsome study site | Staten Island | New York |
United States | Axsome study site | Tampa | Florida |
United States | Axsome study site | Tampa | Florida |
United States | Axsome study site | Temecula | California |
United States | Axsome study site | Toms River | New Jersey |
United States | Axsome Study Site | Topeka | Kansas |
United States | Axsome Study Site | Tucson | Arizona |
United States | Axsome study site | Ventura | California |
United States | Axsome study site | Wichita Falls | Texas |
United States | Axsome Study Site | Winston-Salem | North Carolina |
Lead Sponsor | Collaborator |
---|---|
Axsome Therapeutics, Inc. |
United States, Australia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in CMAI Total Score | The Cohen-Mansfield Agitation Inventory (CMAI) is a 29-item caregiver-rated questionnaire that assesses the frequency of agitation-related and disruptive behaviors in subjects with dementia. The scale contains 29 behaviors or items organized into four subscales: physically aggressive, physically non-aggressive, verbally aggressive, and verbally non-aggressive. The CMAI is administered by interviewing the caregiver and asking him or her to rate the frequency with which the subject manifests each behavior using a seven-point scale: 1=never (better outcome), 7=several times an hour (worse outcome). The CMAI total score is the sum of the scores for all of the items in the CMAI. CMAI total scores range from a minimum of 29 (better outcome) to a maximum of 203 (worse outcome). | 5 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04044495 -
Sleep, Rhythms and Risk of Alzheimer's Disease
|
N/A | |
Completed |
NCT04079803 -
PTI-125 for Mild-to-moderate Alzheimer's Disease Patients
|
Phase 2 | |
Terminated |
NCT03052712 -
Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies
|
N/A | |
Recruiting |
NCT04520698 -
Utilizing Palliative Leaders In Facilities to Transform Care for Alzheimer's Disease
|
N/A | |
Active, not recruiting |
NCT04606420 -
Can Lifestyle Changes Reverse Early-Stage Alzheimer's Disease
|
N/A | |
Recruiting |
NCT05820919 -
Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase
|
N/A | |
Terminated |
NCT03672474 -
REGEnLIFE RGn530 - Feasibility Pilot
|
N/A | |
Completed |
NCT03430648 -
Is Tau Protein Linked to Mobility Function?
|
||
Recruiting |
NCT04949750 -
Efficacy of Paper-based Cognitive Training in Vietnamese Patients With Early Alzheimer's Disease
|
N/A | |
Recruiting |
NCT05288842 -
Tanycytes in Alzheimer's Disease and Frontotemporal Dementia
|
||
Recruiting |
NCT04522739 -
Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease
|
Phase 4 | |
Recruiting |
NCT05557409 -
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation
|
Phase 3 | |
Completed |
NCT06194552 -
A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07
|
Phase 1 | |
Completed |
NCT03239561 -
Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants
|
Early Phase 1 | |
Completed |
NCT03184467 -
Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03676881 -
Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
|
||
Terminated |
NCT03487380 -
Taxonomic and Functional Composition of the Intestinal Microbiome: a Predictor of Rapid Cognitive Decline in Patients With Alzheimer's Disease
|
N/A | |
Completed |
NCT05538455 -
Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases
|
N/A | |
Recruiting |
NCT05328115 -
A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease
|
Phase 1 | |
Completed |
NCT05562583 -
SAGE-LEAF: Reducing Burden in Alzheimer's Disease Caregivers Through Positive Emotion Regulation and Virtual Support
|
N/A |